On The Fly: Analyst Upgrade Summary Today's noteworthy upgrades include: AeroVironment (AVAV) upgraded to Buy from Hold at Benchmark Co... D.R. Horton (DHI) upgraded to Buy from Neutral at UBS... IAC (IACI) upgraded to Overweight from Equal Weight at Barclays... Imperial Tobacco (ITYBY) upgraded to Outperform from Underperform at Exane BNP Paribas... Infinity Pharmaceuticals (INFI) upgraded at JMP Securities.
Infinity Pharmaceuticals price target raised to $21-$25 from $17-$20 at Wells Fargo Wells Fargo increased its price target on Infinity (INFY) after the company announced a global development and commercialization oncology agreement with AbbVie (ABBV) for duvelisib. The firm thinks the financial terms of the deal are favorably for Infinity, and significantly lower the risk presented by Infinity's stock. It raised its estimate of the drug's chances of success to 75% from 65% and keeps an Outperform rating on Infinity.